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Recent studies indicate the chemopreventive role of resveratrol in many animal models like ischemia, rheumatoid arthritis,
human cancer, and diabetes. The present study was designed to investigate the chemopreventive potential of resveratrol in rat
hepatic injury model by carbon tetrachloride. Male Wistar rats were treated with carbon tetrachloride (0.4g/kg body weight)
intraperitoneally daily for 8 weeks. Resveratrol (100mg/kg, 200mg/kg body weight) was given orally from ﬁrst day until the
last day of experiment. The investigation assesses the eﬀect of resveratrol on morphological, oxidative status, histopathological,
immunohistochemical, and apoptotic analysis in carbon tetrachloride-challenged liver tissue. The study indicated that the
inﬂammatory cytokines TNF-α and IL-6 were profoundly expressed in experimental rats, whereas resveratrol decreases the
immunopositivity of TNF-α and IL-6 and restored the altered architectural structure of challenged hepatic tissue. Resveratrol
also protects liver cells by suppressing oxidative stress and apoptosis.
1.Introduction
Liver is a major organ responsible for the metabolism of
drugs and chemicals and also the primary target organ
for many toxic chemicals. The environmental carcinogen,
carbon tetrachloride (CCl4), has been considered as one of
the best characterized experimental model for chemically
induced rat liver damage. CCl4 is a classical hepatotoxicant
causing liver cirrhosis, ﬁbrosis, and necrosis by producing
highly reactive trichloromethyl free radical, initiating lipid
peroxidation and causing centrilobular necrosis. High levels
of reactive oxygen species (ROS) induce cell damage and
are involved in several human pathologies, including liver
cirrhosisandﬁbrosis[1,2].Therefore,theuseofcompounds
with antioxidant properties may prevent or alleviate many
diseases associated with ROS. Formation of ROS is a natu-
rallyoccurringprocess,andmammaliancellshavedeveloped
several protective antioxidant defense mechanisms against
its formation and detoxiﬁcation [3]. ROS are also suggested
to play an important role in cytochrome c release from
mitochondria followed by apoptotic response. Damaging of
kupﬀer cells, hepatic stellates, and sinusoid endothelial cells
resulting in production of pro-inﬂammatory cytokines like
IL-6, TNF-α,T G F - β, eNOS, which are intimately involved in
chemical induced hepatotoxic process [4–7] causes inﬁltra-
tion of neutrophiles and monocytes into the damaged organ
[8, 9]. TNF-α, IL-6 are considered as hepatotoxic in several
experimental models of liver injuries [10, 11].
Resveratrol (3,4 ,5 trihydroxystilbene) is a naturally oc-
curring polyphenol, mainly present in skin of grapes, red
wine,malberries,andpeanuts(Figure 1).Duringthelastfew
years most of the scientiﬁc evidence for resveratrol beneﬁts is
based on in vivo or in vitro studies in which this compound
possesses several pharmacological activities including anti-
cancer[12],antioxidant[13],anti-inﬂammatory[14],antid-
iabetic [15], antinociceptive, and antiasthmatic activity [16].2 Oxidative Medicine and Cellular Longevity
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Figure 1: Structure of trans resveratrol.
Reports also suggest that it has an eﬀective role in glaucoma
[17], pancreatitis [18], and osteoarthritis [19]. It prevents
and cures cardiovascular diseases and improves microcir-
culatory disorders [20]. Resveratrol protects against oxida-
tive stress in cholestasis and exerts hepatoprotective activ-
ity against ethanol- and thioacetamide-induced acute and
chronic liver damage in rodents [21, 22]. Resveratrol at low
doses decreases ischemia-reperfusion-induced liver injury
and protects hepatocytes against antioxidant defense failure
[23]. Resveratrol exhibits immunomodulatory eﬀect by
suppressing overproduction of inﬂammatory cytokines like
TNF-α,I L - 1 β, and IL-6 [24].
Apoptosis is a genetically encoded form of cell suicide
central to the development and homeostasis of multicellular
organisms [25, 26]. Previous report suggested that increased
hepatocyte apoptosis is an important mechanism contribut-
ing to inﬂammation and ﬁbrogenesis of the liver [1]. There is
agrowingevidencetosuggestthatapoptosisisinvolvedinrat
liver damage at the early phase in CCl4-induced liver injury
[27].
The events that trigger apoptosis in CCl4-induced acute
hepatic injury are yet unknown. CCl4-induced toxicity in
isolated hepatocytes is mediated by a direct solvent injury
to cell membranes [28]. Nonparenchymal cells such as
kupﬀer cells are activated by the release of cytokines, which
may contribute to pathophysiological process culminating
in hepatocyte apoptosis after toxic injury to the liver [29].
Therefore, we hypothesize that upon CCl4 insult, cytokines
are expressed in the liver which alter the apoptotic process
and may be reversed by the treatment of resveratrol.
Therefore the present study was undertaken to unveil the
possible chemopreventive approach of resveratrol by exam-
ining the temporal changes of morphological, histopatho-
logical, and TNF-α and IL-6 immunoexpression correlating
with the oxidative stress and apoptotic events in CCl4-
induced subchronic liver damage of male Wistar rats.
2. Results
2.1. Body and Liver Weight. The mean body weights of
diﬀerent groups of rats are shown in Figure 3. No statistical
diﬀerences were seen between the growth rates of any of
the treatment-related groups and control group. A slight
decrease of ﬁnal body weight was observed in CCl4 control
group (group B) as compared to normal control (group
A), though this result was not statistically signiﬁcant. Res-
veratrol-treated groups (group C & D) maintained the
normalbodyweightscomparedtonormalcontrol(groupA),
and it suggested that resveratrol had practically no adverse
eﬀect on the rat growth response. The mean liver weight
along with the relative liver weight of group B (P<0.01)
a n dg r o u pC( P<0.05) is signiﬁcant as compared to normal
control. Whereas no statistical diﬀerence was observed in
group D compared to normal control. Furthermore group
D and group A showed signiﬁcant diﬀerence (P<0.01) as
compared to CCl4 control (Table 1).
2.2. Eﬀect of Resveratrol on CCl4-Induced Nodular Growth.
Visible hepatocyte nodules were not observed in the livers
of normal control (group A), whereas macroscopic nodules
were clearly seen in the CCl4 control rat liver (Figure 4).
Number of rats with nodules, incidence of nodules, total
number of nodules, and nodular multiplicity of CCl4 control
group along with resveratrol-treated groups were shown in
Table 2. A signiﬁcant (P<0.05, P<0.01) decreased inci-
d e n c eo fn o d u l e sw a so b s e r v e di nr e s v e r a t r o l - t r e a t e dg r o u p s
at a dose of 100mg/kg (group C) and 200mg/kg (group D)
as compared to group B; the results were mostly prominent
for group D. Likewise the total number of nodules was found
to be less in all two resveratrol-treated groups as compared
to group B. Nodular multiplicity was found to be signiﬁcant
(P<0.01) in group C and D than group B. When a
comparisonwasmadebetweengroupCandD,asigniﬁcance
(P<0.01) was emerged for the nodule multiplicity.
Resveratrol treatment at a dose of 100mg/kg (group C)
and 200mg/kg (group D) reduced the appearance of nodules
anddecreasedthedevelopmentofnodulesoflessthan3mm,
1mm in size when compared to group B (Table 3). Mean
nodular volume was found to be signiﬁcantly decreased (P<
0.05) in group C as compared to group B. Furthermore, sta-
tisticallysigniﬁcantresultswereobtained(P<0.01)ingroup
D as compared to group B. Nodular volume as a percentage
of liver volume was signiﬁcantly decreased (P<0.05) in
group C in comparison with group B. A signiﬁcant (P<
0.05, P<0.01) decrease in nodular volume as a percentage
of liver volume was observed in all resveratrol-treated groups
as compared to group B. Group D also showed signiﬁcant
(P<0.05) results when compared to group C.
2.3. Eﬀect of Resveratrol on Lipid Peroxidation, Hepatic GSH
and GST. The eﬀects of resveratrol on lipid peroxidation,
hepatic GSH, and GST content in liver tissue were shown
in Table 4. Malondialdehyde (MDA) is the end product
and common marker of lipid peroxidation. The content of
MDA was signiﬁcantly (P<0.01) higher in CCl4 control
group. Treatment with resveratrol 100mg/kg (group C)
and 200mg/kg (group D) signiﬁcantly decreased the MDA
content. As the oxidative stress of tissue generally involves
the GSH and GST system, we measured the level of GSH
and GST in each group of livers. The administration of CCl4
signiﬁcantly depleted GSH and GST content; treatment with
resveratrol signiﬁcantly protected against the GSH and GST
depletion induced by CCl4.
2.4. Eﬀect of Resveratrol on Hepatic Histology. Identiﬁcation
and alteration of histopathological changes during hepa-
tocellular damage and the protective eﬀect of resveratrolOxidative Medicine and Cellular Longevity 3
Table 1: Liver weight and relative liver weight of diﬀerent groups of rats at the end of study (after 8 weeks).
Groups No. of rats Liver weight (g) Relative liver weight (g liver/100g body weight)
A 10 10.5 ± 0.63# 3.62 ± 0.45#
B 10 13.0 ± 1.6∗∗ 4.67 ± 0.7∗∗
C 10 12.2 ± 1.9∗ 4.51 ± 0.35∗
D 10 11.0 ± 1.2# 3.88 ± 0.4#
Group A, normal control; group B, CCl4 administered rats; group C, resveratrol-(100mg/kg) treated rats; group D, resveratrol-(200mg/kg) treated rats.
Results are mean ± S.E.M for 10 animals; One way ANOVA followed by Dunnett’s multiple comparison test.
∗indicates value signiﬁcantly diﬀerent from the normal control at P<0.05.
∗∗indicates value signiﬁcantly diﬀerent from the normal control at P<0.01.
#indicates value signiﬁcantly diﬀerent from the CCl4 control at P<0.01.
Table 2: Eﬀect of resveratrol treatment on the development of microscopic hepatocyte nodules induced by CCl4 in male Wistar rats.
Groups No. of rats with
nodules/total rats Nodule incidence (%) Total no. of nodules Average no. of nodules/nodule-bearing
liver (nodule multiplicity)
B 10/10 100 246 24.6 ±2.4
C6 / 1 0 6 0 ∗ 65 10.8 ±1.3
∗∗
D3 / 1 0 3 0 ∗∗ 21 7 ±1.6
∗∗#
Group B, CCl4-administered rats; group C, resveratrol-(100mg/kg) treated rats; group D, resveratrol-(200mg/kg) treated rats.
Results are mean ± S.E.M for 10 animals; One way ANOVA followed by Dunnett’s multiple comparison test.
∗P < 0.05 and ∗∗P < 0.01 as compared with group B.
#P<0.05 as compared with group C.
Animals from group A did not show visible hepatocyte nodules.
against CCl4-induced toxicity were depicted in Figure 5.
Histopathology of liver from the normal control (group A)
showed a regular arrangement of hepatocytes with clearly
visible nuclei (Figure 5(a)). Intraperitoneal injection of CCl4
at a dose of 0.4g/kg body weight (group B) showed extensive
centrilobular necrosis around the central vein of liver and
dilation of the central vein with few regenerative areas of
hepatocytes around the central vein, and distal part of liver
was observed (Figure 5(b)). The magnitude of dilation of
the central vein was prominent but very less in group C as
compared with CCl4 control group (group B) (Figure 5(c)).
The liver sections from group D showed good protection of
hepatocellular necrosis with a poorly dilated central vein and
regular arrangement of hepatocytes around the central vein.
The distal part of the liver from the central vein was observed
along with a scattered regenerative zone of hepatocytes; very
few necrotic zones were prominent (Figure 5(d)).
2.5. Eﬀect of Resveratrol on Expression of TNF-α. The expres-
sion of TNF-α was analyzed by immunohistochemistry
(Figure 6), and percentage of TNF-α immunopositive cells
in liver tissues of various groups of experimental rats were
shown in Table 5. The liver sections of normal control
showed complete absence of immunostaining of TNF-α
(Figure 6(a)). A large amount of TNF-α immunopositive
cells (28.5 ± 2.4) were detected in the liver tissue sections
of the CCl4 control rats (group B) (Figure 6(b)). In contrast,
thedecrementofTNF-αimmunopositivity(15.3±3.6),(P<
0.05)wasobserveduponresveratrol-(100mg/kg)treatedrats
comparedtoCCl4 control(Figure 6(c)).Furthermoreamore
decrement of TNF-α immunopositivity was marked (10.6 ±
4.7, P<0.01) in resveratrol-(200mg/kg) treated rats
compared to CCl4 control group (Figure 6(d)).
2.6. Eﬀect of Resveratrol on Expression of IL-6. Figure 7
depicted the representative photomicrographs of immuno-
histochemical staining of IL-6 in liver tissues. Table 5
showed the expression of IL-6 immunopositive cells (as
percentage) of various groups of experimental rats. The
liver sections of normal control showed complete absence
of immunostaining of IL-6 (Figure 7(a)). A large amount
of IL-6 immunopositive cells (18.2 ± 0.7) were detected
in the liver tissue sections of the CCl4 control rats
(group B) (Figure 7(b)). In contrast, the decrement of IL-6
immunopositivity was observed (12.4 ± 0.3, P<0.05) upon
resveratrol (100mg/kg) treatment compared to CCl4 control
(Figure 7(c)). A more decrement of IL-6 immunopositivity
was observed (8.2±0.6, P<0.01) in resveratrol-(200mg/kg)
t r e a t e dr a t sc o m p a r e dt oC C l 4 control (Figure 7(d)).
2.7. Estimation of TNF-α and IL-6 by ELISA. Levels of
cytokines (TNF-α and IL-6) in liver homogenate were shown
in Figure 8. The levels of TNF-α (Figure 8(a))a n dI L - 6
(Figure 8(b)) were signiﬁcantly (P<0.01) elevated in
CCl4 control group. Treatment with resveratrol at the dose
100 and 200mg/kg signiﬁcantly (P<0.01) reduced the
level of inﬂammatory cytokines. In addition with these, the
eﬀect of resveratrol at 200mg/kg was found more signiﬁcant
(P<0.01) when compared to resveratrol-100mg/kg-treated
group.
2.8. Eﬀect of Resveratrol on Apoptosis. The CCl4 injection
caused necrosis along with apoptosis in a dose- and duration
dependent-manner in experimental animal models. The
immunohistochemical analysis of apoptosis was performed
by TUNEL method (Figure 9). The chromogen-generated4 Oxidative Medicine and Cellular Longevity
Table 3: Eﬀect of resveratrol on the size distribution and growth of hepatocyte nodules induced by CCl4 in rats.
Groups No. of rats with nodules
Nodules relative to size (% of total no.)
Mean nodular volume (cm3) Nodular volume/liver
volume (%) <3–>1mm <1mm
B1 0 5 9 ± 74 1 ± 14 0.17 ± 0.04 1.3 ± 0.34
C6 4 9 ± 15 51 ± 12 0.06 ± 0.02∗ 0.49 ± 0.14∗
D3 3 1 ± 12 69 ± 70 . 0 3 ± 0.05∗∗ 0.30 ± 0.22∗∗#
Group B, CCl4-administered rats; group C, resveratrol-(100mg/kg) treated rats; group D, resveratrol-(200mg/kg) treated rats.
Results are mean ± S.E.M for 10 animals; One way ANOVA followed by Dunnett’s multiple comparison test.
∗P < 0.05 and ∗∗P < 0.01 as compared with group B.
#P<0.05 as compared with group C.
Animals from group A did not show any visible hepatocyte nodule.
Table 4:Eﬀectoftheresveratroltreatment(100mg/kg,200mg/kgbodyweight)for8weeksonthelipidperoxidation,glutathionereductase,
and glutathione-s-transferase in liver tissue of CCl4-induced rats.
Group TBARS (nmol/g liver weight) GSH content (nmol/mg protein) GST content (nmole/min/mg protein)
A 106 ±2.4
∗∗ 110 ±2.2
∗∗ 1622 ±3.2
∗∗
B 303 ±3.27 5 ±1.5 720 ±2.5
C 210 ±3.5
∗ 90 ±2.2
∗ 1145 ±2.4
∗
D 129 ±2.7
∗∗# 107 ±1.2
∗∗# 1543 ±3.6
∗∗#
Group A, normal control; group B, CCl4-administered rats; group C, resveratrol-(100mg/kg) treated rats; group D, resveratrol-(200mg/kg) treated rats.
Results are mean ± S.E.M for 10 animals; One way ANOVA followed by Dunnett’s multiple comparison test.
∗P < 0.05 and ∗∗P < 0.01 as compared with group B.
#P<0.05 as compared with group C.
Table 5:TheexpressionofTNF-αandIL-6immunopositivecellsof
the CCl4-induced liver tissue after 8 weeks of resveratrol treatment.
Groups TNF-α (%) IL-6 (%)
B2 8 .5 ±2.41 8 .2 ±0.7
C1 5 .3 ± 3.6
∗ 12.4 ± 0.3
∗
D1 0 .6 ± 4.7
∗∗ 8.2 ± 0.6
∗∗
The expression of TNF-α, IL-6 was not detectable in livers of normal control
group rats.
Approximately, 200 cells were counted per ﬁeld, ﬁve ﬁelds were examined
per slide, and ﬁve slides were examined per group.
Values are presented as mean ± S.E.M and results were analyzed by One way
ANOVA conﬁrmed by Dunnett’s test as appropriate using graph pad prism.
∗P < 0.05 and ∗∗P < 0.01 as compared with Group B.
brown stain is an indication of apoptotic cells. It should be
noted that in almost every case, the brown stain overlaps the
condensed chromatin of apoptotic bodies, thus conﬁrming
that the TUNEL assay correlates well with the morphological
appearance of apoptosis. The rate of apoptosis was gener-
ally very low in normal control group (Figure 9(a)), and
more positive staining was expressed in CCl4-induced liver
sections (Figure 9(b)). Less apoptotic cells were observed in
resveratrol-treatedgroups(groupCandD)(Figures9(c)and
9(d)). The percentage of TUNEL positive apoptotic cells was
denoted as apoptotic index. The apoptotic index value of
group B was found as 21.3 ± 1.2. Reduction of apoptosis
(13.71 ± 0.17) by resveratrol (100mg/kg) was statistically
signiﬁcant (P<0.05) as compared to group B. Further-
more, the reduction of apoptosis (10.6 ± 0.28) in high
dose of resveratrol (200mg/kg) was more statistically sig-
niﬁcant (P<0.01) when compared to CCl4 control group.
The apoptotic index value of group D was signiﬁcantly less
(P<0.05) as compared to group C.
3. Discussion
The antioxidant and free radical scavenging activities of
many substances have been assessed, and reports suggested
that compounds having strong antioxidant activity showed
promising hepatoprotective activity [30, 31]. Polyphenolic
compounds, which are widely distributed in fruits, are
considered to play an important role as dietary antioxidants
for the prevention of oxidative damage during pathogenesis
[32]. Therefore, we hypothesized that resveratrol, a polyphe-
nolic compound, would be beneﬁcial in the prevention of
various liver injuries induced by oxidative stress.
LiverinjuryinducedbyCCl4 isthebestcharacterizedsys-
tem of xenobiotic induced hepatotoxicity and is a commonly
used model for screening hepatoprotective drugs [33–35].
Earlier studies described the eﬀect of resveratrol on acute
liver damage induced by high dose of CCl4 [36]. Resveratrol
was found to prevent ﬁbrosis by reduction of NF-kappaβ
activation and TGF-β content in CCl4 induced liver damage
in rats [37]. Our data ﬁrst indicates that subchronic CCl4
treatment provoked a clear toxicity in rats, as assessed by
morphological variations reﬂected by markedly increased
and localized in hepatic nodules, alteration of oxidative
status and histopathological architecture of hepatic tissue,
and overexpression of proinﬂammatory cytokines. Till now,
the chemopreventive studies of resveratrol against CCl4-
induced subchronic toxicity and its relation with apoptosis
andlevelsofinﬂammatorycytokineshavenotbeenreported.
In present study it has been recognized that CCl4-inducedOxidative Medicine and Cellular Longevity 5
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Figure 2: Schematic representation of experimental regimen.
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Figure 3: Eﬀect of resveratrol on body weight gain during hepatic
damage in rats. No signiﬁcant diﬀerence in body weight was
detected among the four groups.
hepatotoxicity is mediated through an apoptotic mode of
action of hepatocytes secondary to the cytolethality. Resver-
atrol appears as a good candidate in the prevention of CCl4-
inducedratliverinjury.Inourpresentstudy,thebodyweight
of experimental animals was not altered, and this may be
considered to be an important aspect of resveratrol action.
The ﬁndings of the present investigation demonstrated
that resveratrol treatment greatly reduced CCl4-initiated
hepatic damage in rats, and administration of resveratrol
by oral route ameliorates nodule formation. Even though
during the life span of animals not all the hepatocyte nodules
become malignant but numerous studies support that the
neoplastic/hyperplastic nodules are the precursors of hepatic
cancer.Inpresentstudy,theeﬀectofresveratroloninhibition
of nodule growth and enhancement of their regression was
observed.
Previous studies suggested that GSH plays a key role in
detoxifying the reactive toxic metabolites of CCl4.F a i l u r et o
detoxify the metabolites promotes liver necrosis [38, 39].
GSH form adducts with the toxic metabolites of CCl4 and
contributes to the detoxiﬁcation of CCl4. It has been sug-
gested that one of the principal causes of CCl4-induced liver
injury is lipid peroxidation caused by its free radical deriva-
tives [38]. GST is a soluble protein located in the cytosol
that plays an important role in the detoxiﬁcation and excre-
tion of xenobiotics [40]. Moreover, GST functionally binds
with GSH and endogenous and exogenous substances. Our
ﬁndings showed that treatment with resveratrol signiﬁcantly
inhibited lipid peroxidation, reduced CCl4-induced hepatic
GSH depletion, and enhanced the GST activity.
Histological ﬁndings clearly showed that the normal
architecture of the hepatic tissue was altered due to admin-
istration of CCl4-released reactive oxygen species causing6 Oxidative Medicine and Cellular Longevity
(a) (b) (c) (d)
Figure 4: Morphological examination of rat liver tissue at the end of the study. Macroscopically visible hepatic nodules were shown by
arrows. Representative livers are taken from several groups: (a) Normal control (group A); (b) CCl4 c o n t r o l( g r o u pB ) ;( c )R e s v e r a t r o l
100mg/kg + CCl4 (0.4g/kg) (group C); (d) Resveratrol 200mg/kg + CCl4 (0.4g/kg) (group D).
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Figure 5: Histological proﬁle of representative liver tissue in experimental animals. (a) Normal control rat liver (group A). Arrow 1 indicates
the normal structure of central vein with radially arranged hepatocytes around it. Arrow 2 indicates normal hepatocytes (H & E X 200);
(b) CCl4 control (group B). Arrow 3 showed dilation of the central vein with few regenerative areas of hepatocytes around the central vein
and distal part of liver. 4, 5 arrow showed extensive centrilobular necrosis around the central vein of liver (H & E X 200); (c) section from
resveratrol (100mg/kg) + CCl4 (group C) arrow 6 represents the magnitude of dilation of the central vein (H & E X 200); (d) section from
resveratrol (200mg/kg) + CCl4 ( group D) arrow 7 showed good protection of hepatocellular necrosis with a poorly dilated central vein and
regular arrangement of hepatocytes around the central vein and also the distal part of the liver from the central vein along with a scattered
regenerative zone of hepatocytes; very few necrotic zones were prominent showing hepatocytes maintaining nearnormal architecture (H &
E X 200).
degeneration in hepatocytes, extensive centrilobular necrosis
around the central vein of liver. In contrast, rats treated with
resveratrol showed noticeable improvement in histopatho-
logical parameters. There was no sign of necrotic region and
dilation of central vein. Our result is also at per of recent
ﬁndings that resveratrol protects primary rat hepatocytes
against cell damage induced by reactive oxygen species [41].
In this study, we analyzed the inhibitory eﬀect of resver-
atrol on the release of proinﬂammatory cytokines in CCl4-
inducedrathepaticdamagemodel.Cytokinesserveascentral
regulators controlling genes, responsible for either inducing
apoptosis or protective action on cell by stimulating prolifer-
ation of hepatocyte. Cytokines constitute a complex network
involved in the regulation of inﬂammatory responses andOxidative Medicine and Cellular Longevity 7
(a) (b)
(c) (d)
Figure 6: Immunohistochemical localisation of TNF-α in the rat liver tissue (H & E X 100). The ﬁgure shows representative staining for
TNF-α (DAB) against counterstain (hematoxylin). (a) Represents normal liver (group A); (b) represents CCl4 control liver (group B); (c)
represents resveratrol (100mg/kg) + CCl4 (group C); (d) represents section from resveratrol (200mg/kg) + CCl4 (group D). The liver
sections of control animals are mainly negative. Liver sections of CCl4-exposed rats show more intensive staining.
(a) (b)
(c) (d)
Figure 7: Immunohistochemical localisation of IL-6 in the rat liver tissue (H & E X 100). The ﬁgure shows representative staining for TNF-α
(DAB) against counterstain (hematoxylin). (a) Represents normal liver (group A); (b) represents CCl4 control liver (group B); (c) represents
resveratrol(100mg/kg)+CCl4 (groupC);(d)representssectionfromresveratrol(200mg/kg)+CCl4 (groupD).Theliversectionsofcontrol
animals are mainly negative. Liver sections of CCl4 exposed rats show more intensive staining.8 Oxidative Medicine and Cellular Longevity
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Figure 8: Levels of inﬂammatory cytokines TNF-α (a), and IL-6 (b) by ELISA in liver homogenate. Group A—Normal control; Group B—
CCl4 control; Group C—resveratrol (100mg/kg) + CCl4; Group D—resveratrol (200mg/kg) + CCl4. The values are expressed as mean ±
SEM (n = 10);
∗P < 0.01 as compared with Group B; #P < 0.01 as compared to group C.
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(c) (d)
Figure 9: Apoptotic assay was performed by using TUNEL assay (H.E. X 400); brown stained cells (indicated by arrows) are undergoing
apoptosis. (a) Immunostaining of rat liver from normal control (group A) showed absent of brown staining, (b) CCl4 c o n tr o l( gr o u pB )l i v e r
showing more staining indicative cells undergoing apoptosis; (c) resveratrol (100mg/kg) + CCl4 (group C) exhibited less cells undergoing
apoptosis; (d) resveratrol (200mg/kg) + CCl4 (group D) exhibited very few number of brown-stained nuclei.
maintain homeostasis of organ functions. Major hepatotoxic
mediators in several experimental models of liver injury
are TNF-α and IL-6. TNF-α is a circulating factor which
causes necrosis of tumors when administered to tumor-
bearing mice. These levels are elevated in both inﬁltrating
inﬂammatory cells and hepatocytes in chronic liver injuries
including viral or alcoholic liver diseases, hepatitis, ischemia,
and biliary obstruction [42]. Exposure to hepatotoxic chem-
icals facilitates TNF-α to induce necrotic cell death and
hepatic apoptosis [43]. IL-6 is a multifunctional cytokine
alongwithTNF-αactivateshepaticstellatecellsandincreases
the production of extracellular matrix proteins that ﬁnally
leads to cirrhosis. Elevation of IL-6 concentration after
hepaticinjurysuggestedapotentialroleofIL-6inhepatocyte
proliferation,butsomestudiesdemonstratedthathepatocyte
regeneration was impaired in IL-6 deﬁcient mice [44]. In our
recent ﬁndings, overexpression of TNF-α and IL-6 in CCl4
control rats was markedly reduced by resveratrol-treated
groups.
It was well documented that necrosis in the centrilobular
zone is beloved to the injury of hepatocytes. However both
necrosisandapoptosiscanbecausedbydrugsandchemicals.Oxidative Medicine and Cellular Longevity 9
It was studied that apoptosis is preprogrammed form of
cell death which is characterized by organized cellular frag-
mentation; remnants resulting from this structured decay,
termed apoptotic bodies, are then cleared by phagocyto-
sis. Pathological rates of unregulated apoptosis associated
with an enhanced inﬂammatory response and ﬁbrosis. We
investigated the possible role of apoptosis in the carbon
tetrachloride-inducedliverinjuryanditsrelationwithchem-
opreventive nature of resveratrol. Our results indicate that
cell loss by apoptosis occurred profoundly and rapidly in
thecarbontetrachloride-challengedliverandexpressedmore
number of TUNEL positive cells. Suppression of apoptotic
incident was observed by resveratrol-treated groups.
In conclusion the protective eﬀect of resveratrol was con-
ﬁrmed in a well-deﬁned rat model of carbon tetrachloride-
induced liver injury. Recently much attention is focused on
the protective functions of naturally occurring antioxidants
in biological systems and their mechanisms. This study
provides biological evidence that supports the use of resver-
atrol in the treatment of liver disorder. Downregulation of
apoptosis and suppression of inﬂammatory cytokines levels
can be attributed to molecular mechanism of hepatopro-
tective activity of resveratrol. Considerable eﬀorts are being
undertakentodevelopspeciﬁcandsafebiologicalandmolec-
ular inhibitors of TNF-α and IL-6 for potential therapeutic
use. The understanding of the molecular basis for inﬂam-
matory diseases to improve human health risk assessment
and also identiﬁcation of functional polymorphisms for
inﬂammatory mediators should allow for a better estimation
of determining susceptible populations and help to improve
human risk assessment.
4.MaterialsandMethods
4.1. Chemicals. Resveratrol, carbon tetrachloride (CCl4),
thiobarbituric acid reagent (TBA), reduced glutathione
(GSH), biotinylated rabbit anti-mouse IgG, streptavidin per-
oxidase, antidigoxigenin peroxidase, 3,3 diaminobenzidine
tetrahydro chloride (DAB), terminal deoxynucleotidyl trans-
ferase (TdT), and deoxyuridine triphosphate (dUTP) were
obtained from Sigma Chemical Company (St. Louis, Mo,
USA). ELISA kit was purchased from BD Bioscience (San
Jose,Calif,USA).Glutathione-S-transferasedetectionkitwas
purchased from Stratagene (La jolla, Calif, USA). The
rabbit anti-mouse TNF-α and IL-6 antibody procured from
Anaspec Inc. (San Jose, Calif, USA). All other chemicals and
reagents were used of analytical grade purchased purest form
available from local ﬁrms.
4.2. Animals and Diet. Pathogen-free male Wistar rats,
initially weighing 100–150g, were obtained from Indian
Institute of Chemical Biology (IICB, Kolkata, India). The
animals were acclimatized to standard laboratory conditions
(temperature 18C ± 2C, relative humidity 40% to 70% and
a 12h:12h light/dark cycle) and housed in solid bottom
polypropylene cages (four animals per cage) bedding for one
week before starting the experiment. The animals were fed
with a semipuriﬁed basal diet and demineralized drinking
water ad libitum. The recommendations of “Institutional
Animal Ethical Committee” [Committee for the Purpose
of Control and Supervision of Experiments on Animals
(CPCSEA Regn. no. 1126/bc/07CPCSEA) India] for the
care and use of laboratory animals were strictly followed
throughout the experiment.
4.3. Induction of Hepatic Injury. The experimental hepatic
injury was initiated by intraperitoneal injection of carbon
tetrachloride (0.4g/kg/day) dissolved in puriﬁed mineral oil
and continued up to 8 weeks. It is an important xenobiotic
swallowing or inhalation exposure of CCl4 over a period of
time which increases the frequency of liver damage in
animals [45].
4.4. Resveratrol Dose Selection. The doses of resveratrol
100mg and 200mg/kg bodyweight/day were selected based
on previously reported chemopreventive and toxicological
properties of this compound in rats. These doses have been
found to suppress diethyl nitrosamine-initiated hepatocar-
cinogenesis in rodent model [46]. Resveratrol is not soluble
in water therefore administered by suspended in 0.7% of
carboxymethyl cellulose.
4.5. Experimental Design. After acclimatization, rats were
divided randomly into four groups with ten animals each
(Figure 2). Normal control (group A) was treated with
0.1mL of mineral oil and CCl4 control (group B) was
treated with CCl4 (0.4g/kg/day). Treatment group (group C)
animals received resveratrol at a concentration of 100mg/kg
orally along with CCl4 (0.4g/kg/day) and continued up to 8
weeks. Another group (group D) was treated with resveratrol
at a concentration of 200mg/kg orally along with CCl4
(0.4g/kg/day) and continued up to 8 weeks. Body weights
of animals were recorded every one week. After 8 weeks, ani-
malswerekept forovernight fastingandsacriﬁcedrandomly.
Liver sections were collected and used for further experi-
ment.
4.6. Morphology. Animals from each group were sacriﬁced
with ether anesthesia. The livers were quickly excised, rinsed
with ice-cold phosphate-buﬀered saline (pH 7.4) to ﬂush
out any blood, blotted dry on a paper towel, weighed,
and photographed. Each liver was examined macroscopically
on the surface as well as in 3mm cross-sections for gross
visible hepatocyte nodules from all groups of the rats. The
nodulesweremeasuredwithaverniercaliperthroughitstwo
perpendicular planes to the nearest mm to obtain an average
diameter of each nodule. The nodules were counted and
categorized into two groups according to their respective
diameters (<3–>1a n d<1mm). Nodular volume (V)w a s
determined by using the formula
V =
4
3
πr3,( 1 )
where r = half of the average diameter (mm).10 Oxidative Medicine and Cellular Longevity
Table 6: Quantiﬁcation of hepatic apoptosis of rats at the end of
the study.
Groups Apoptotic indexa (AI)
B2 1 .3 ±1.2
C1 3 .71 ±0.17
∗
D1 0 .60 ±0.28
∗∗
Group B, CCl4-administered rats; group C, resveratrol-(100mg/kg) treated
rats; group D, resveratrol-(200mg/kg) treated rats. Results are mean ±
S.E.M for 10 animals; One way ANOVA followed by Dunnett’s multiple
comparison test.
∗P < 0.05 and ∗∗P < 0.01 as compared to group B.
Approximately200cellswerecountedperﬁeld,ﬁveﬁeldswereexaminedper
slide, and ﬁve slides were examined per group.
aThepercentageofTUNELpositiveapoptoticcellswasdenotedasapoptotic
index (AI).
4.7. Assessment of Lipid Peroxidation. Hepatic lipid peroxi-
dation levels were determined by measuring thiobarbituric
acid-reactive substance (TBARS) [47]. Samples were mixed
with thiobarbituric acid (TBA) reagent consisting of 0.375%
TBA and 15% trichloroacetic acid in 0.25N hydrochloric
acid. The reaction mixtures were placed in a boiling water
bath for 30min. The samples were centrifuged (2000rpm
for 10min at 48◦C), and the TBARS concentration was de-
termined based on the absorbance at 532nm measured with
a spectrophotometer at room temperature.
4.8. Hepatic GSH and GST Activity. Livers were quickly
removed and weighed and perfused with ice-cold 0.15M
KCl and then homogenized with 4 volumes of 10mM tris-
HCl(pH7.4)containing0.15MKCl,0.1mMEDTA,1.0mM
dithiothreitol, and 0.01mM phenylmethylsulfonyl ﬂuoride
in an Ultra Turrax tissue homogenizer. Hepatic GSH levels
were estimated colorimetrically (Systronic 2202, Ahmed-
abad, India) using Ellman’s reagent [48]. Cytosolic GST
activity was determined using 1-chloro-2,4-dinitrobenzene
as a substrate [49].
4.9. Histopathology. Eight weeks after the CCl4 or vehicle
treatment animals from each group were randomly selected;
a portion of the liver was excised from ether-anaesthetized
ratﬁxedin10%formalinandprocessedforhistopathological
studies. The tissues were dehydrated through 70, 90, and
100% alcohol and embedded in low melting point paraﬃn
wax. Section of 5μM thickness was cut and placed serially
on glass slide. Each liver tissue was stained with hema-
toxylin and eosin for histopathological evaluation using light
microscopy.
4.10. Immunostaining of TNF-α,I L - 6 .Immunohistochem-
ical detection of TNF-α and IL-6 in cold acetone ﬁxed,
paraﬃn-embedded liver sections was performed by the
avidin-biotin-peroxidase complex method. Brieﬂy 5μM thin
sections of lysine coated slides were deparaﬃnised and
rehydrated. For immunolabeling of TNF-α and IL-6 antigen
retrieval was facilitated by heating the sections in citrate
buﬀer pH 6.0, for 20min. Endogenous peroxidase activity
was blocked with 1% H2O2 in 0.1M Tris-NaCl, (pH 7.6) for
30min. After incubated in 5% normal goat serum, sections
were then separately incubated overnight at 4◦C with the
primary puriﬁed anti-mouse TNF-α antibody,primarypuri-
ﬁedanti-mouseIL-6antibodyat1:50dilutions,respectively,
in 1% bovine serum albumin (BSA). Sections were then
incubated with a biotinylated secondary antibody, goat anti-
rabbit IgG (Sigma) for 30min at 37◦C with 1:100 dilutions.
Thiswasfollowedbyincubationwithstreptavidinperoxidase
(1:100) for 1h. After that 100–400μL of diaminobenzidine
tetrahydrochloride(DAB)reagentwasaddedtoeachsection.
As soon as sections turn brown, the slides are immersed in
double-distilled water (ddH2O )t w ot i m e sf o r5 m i ne a c h .
T h es e c t i o n sw e r ed e h y d r a t e da n dm o u n t e dw i t hD P Xa n d
served as a positive control. The percentage of immunoposi-
tive cells was counted under a light microscope.
4.11. Enzyme-Linked Immunosorbent Assays (ELISA). Hep-
atic TNF-α and IL-6 levels were estimated using commercial
ELISAkitpurchasedfromBDBiosciences(SanJose,Calif)as
per the protocol provided by the manufacturer. Microplates
were coated with 100μL/well of capture antibody and incu-
bated overnight at 4◦C. After washes, the plates were blocked
with assay diluent (BD Biosciences) at room temperature
(RT) for 1h. One hundred microliters of liver homogenate
in PBS supplemented with protease inhibitors, were added
to each well of the plate, followed by incubation for 2h at
RT.Workingdetector(100μL)wasloadedintoeachwell,and
the plate was incubated for an additional 1h at RT before
the addition of 100μL substrate solution. The reaction was
stopped by adding 50μL stop solution. The absorbance was
read at 450nm, with reference wavelength at 570nm using
a 96-well plate spectrometer (SpectraMax 190; Sunnyvale,
Calif). Calculation of the concentrations of the cytokines
was performed in a log-log linear regression according to the
instructions in the protocol.
4.12. Apoptosis by TUNEL Assay. Apoptotic cells in liver
tissue sections were determined by TUNEL assay. The sec-
tions were digested with proteinase K (20μg/mL in PBS) for
15minatroomtemperatureandrinsedwithdouble-distilled
water. Slides were then quenched by 2% H2O2 for 5min
at room temperature, equilibrated with buﬀer. Slides were
then incubated with terminal deoxynucleotidyl transferase
(TdT) buﬀer (30mM Trizma base, pH 7.2, 140mM sodium
cacodylate, 1mM cobalt chloride), followed by TdT reaction
solution containing TdT and deoxyuridine triphosphate
(dUTP) for 90min at 37◦C, then washed with 2% standard
saline citrate to stop the reaction for 10min at room temper-
ature. The slides were then washed with PBS for 5min each
and incubated with antidigoxigenin peroxidase for 30min
(1:100) at room temperature. Color was developed using
0.05% of diaminobenzidine tetrahydro chloride (DAB Kit
Sigma, St. Louis, Mo, USA) in 0.01% H2O2 diluted with
tris-HCl (pH 7.5), then lightly counterstained with leishman
stain. Sections were then washed, dehydrated, and mounted.
Apoptotic cells were identiﬁed by a brown stain over the
nuclei. Approximately 200 cells were counted per ﬁeld, ﬁve
ﬁelds were examined per slide, and ﬁve slides were examinedOxidative Medicine and Cellular Longevity 11
per group. Apoptotic index (AI) was determined as the per-
centageof labelled cells (TUNEL positive) with respect to the
total number of cells counted using (see Table 6)
Apoptotic index (AI)
=

number of labeled cells
total number of cells counted

× 100.
(2)
4.13. Statistical Analysis. T h ed a t aa r ee x p r e s s e da sm e a n s±
S.E.M.ComparisonsarecarriedoutbyOnewayANOVAfol-
lowed by posttest (Dunnett’s test) as appropriate using graph
pad prism. Results were considered statistically signiﬁcant,
when P<0.01, P<0.05.
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